Related Experiment Video
Updated: Sep 11, 2025
04:48
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
7.5K
Cisplatin-Based Combinations-Associated Vasculopathy - A Disproportionality Analysis of Real-World Pharmacovigilance
Krutarth K Pandya1, Chitsimran Mann2, Wei Fang3
1Department of Cardiology, Cleveland, Ohio, 44195, USA.
Current Drug Safety
|August 13, 2025
Summary
Cisplatin chemotherapy combinations are linked to increased vascular events, particularly with gemcitabine. Healthcare providers should monitor patients for thrombotic events during treatment.
Area of Science:
- Oncology
- Pharmacovigilance
- Cardiovascular Medicine
Background:
- Cisplatin is a widely used chemotherapy agent for solid tumors and hematologic malignancies.
- While effective, cisplatin is associated with toxicities like nephro-, gastrointestinal-, and hepatotoxicity.
- Limited data exists on cisplatin's association with adverse vascular events.
Purpose of the Study:
- To investigate the risk of drug-related adverse vascular events associated with four cisplatin-based combination therapies.
- Utilized the FDA Adverse Events Reporting System (FAERS) for analysis.
Main Methods:
- Case/non-case disproportionality analysis using Reporting Odds Ratio (ROR) on 2016-2020 FAERS data.
- Included peripheral, cerebrovascular, coronary, venothromboembolic, and arterial events.
- Analyzed four cisplatin combination groups: cisplatin/etoposide, cisplatin/gemcitabine, cisplatin/paclitaxel, and cisplatin/docetaxel.
Main Results:
- All four cisplatin-based combination groups showed statistically significant vasculopathies.
- Cisplatin and gemcitabine combination exhibited the highest signal for associated vasculopathy (ROR and IC).
- Cisplatin and paclitaxel/docetaxel showed a trend but did not reach statistical significance for vasculopathy.
Conclusions:
- Increased vasculopathies linked to cisplatin combinations may stem from a pro-thrombotic state.
- Highlights the need for caution and monitoring for thrombotic events in patients receiving cisplatin-based chemotherapy.
- Emphasizes considering patient-specific factors for treatment decisions and managing vascular risks.
Related Concept Videos
01:19Pharmacovigilance
993
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
993
01:12Analysis of Population Pharmacokinetic Data
383
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
383
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259